Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemilukast SCHEMBL597344 | 1.00 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL598642 | 0.93 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| Gemilukast SCHEMBL597425 | 0.92 | CYSLTR2 (0.86) | CYSLTR2CYSLTR1 | |
| Gemilukast SCHEMBL598116 | 0.92 | CYSLTR2 (0.84) | CYSLTR2CYSLTR1 | |
| Gemilukast SCHEMBL597080 | 0.91 | CYSLTR2 (0.83) | CYSLTR2CYSLTR1 | |
| Gemilukast SCHEMBL597081 | 0.91 | CYSLTR2 (0.83) | CYSLTR2CYSLTR1 | |
| SCHEMBL598035 | 0.90 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL597067 | 0.89 | CYSLTR2 (0.88) | CYSLTR2CYSLTR1 | |
| SCHEMBL597788 | 0.87 | CYSLTR2 (0.89) | CYSLTR2CYSLTR1 | |
| SCHEMBL10143243 | 0.86 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3684954-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | GENFIT (FR) | 2025-11-26 | — | — | EP | disclosed |
| EP-3612176-B1 | COMBINATION COMPRISING THE PPAR AGONIST ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR SELECTED FROM CP-640186, GEMCABENE, GS-0976 TO TREAT INFLAMMATORY, METABOLIC, FIBROTIC OR CHOLESTATIC DISEASES | GENFIT (FR) | 2025-09-17 | — | — | EP | disclosed |
| CN-110461839-B | JAK inhibitors containing 4-membered heterocyclic amides | 施万生物制药研发IP有限责任公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220241232-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | GENFIT (FR) | 2022-08-04 | — | — | US | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-110382498-B | Fused imidazole-piperidine JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2022-05-26 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3985126-A1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | Genfit (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3980070-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | Genfit (FR) | 2022-04-13 | — | — | EP | disclosed |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | MITOPOWER LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MitoPower, LLC (US) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062314-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | CYSLTR2 4170/4885CYSLTR1 3903/4885 |
| US-11286274-B2 | Nicotinamide riboside derivatives and their uses | NME4, NADK, NQO1 | CYSLTR2 3450/4885CYSLTR1 3112/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | CYSLTR2 1660/4885CYSLTR1 1868/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | CYSLTR2 3109/4885CYSLTR1 3162/4885 |
| US-20220241232-A1 | METHOD FOR TREATMENT OF AT RISK PATIENTS | SLC10A1, CPT1A, FABP1 | CYSLTR2 188/4885CYSLTR1 450/4885 |
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | NQO1, DOHH, DHODH | CYSLTR2 3184/4885CYSLTR1 3146/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | CYSLTR2 1645/4885CYSLTR1 2482/4885 |
| US-20220162702-A1 | DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, FABP2 | CYSLTR2 892/4885CYSLTR1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.